San Francisco, CA, United States of America

Peter J Kushner

This inventor holds 17 USPTO granted patents and 11 published patent applications, plus 1 CIPO patent and 2 EPO patents, primarily in Estrogen Receptor Research. Top assignees: University of California, Olema Pharmaceuticals, Inc., California Biotechnology Inc.. Active years: 1992-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Peter J Kushner. Retrieved from https://idiyas.com/inventor/peter-j-kushner

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 11)

% Patents Active = 82.4

CIPO Patents = 1 (Patent Applications = 6)

EPO Patents = 2 (Patent Applications = 7)

Average Co-Inventor Count = 4.2

ph-index = 6

Forward Citations = 122(Granted Patents)

Company Filing History:

8 out of 16,035

University of California

patents

7 out of 8

Olema Pharmaceuticals, Inc.

patents

1 out of 21

California Biotechnology Inc.

patents

4. 1 out of 834,570

Other

patents

Years Active: 1992-2025

Loading Chart...

Areas of Expertise:

Estrogen Receptor Antagonists

Anti-Estrogenic Drugs

Nuclear Receptor Ligands

Breast Cancer Treatments

Transgenic Mice

Tyrosine Kinase Receptor

Inhibitors

Transcription Factor

Binding Domains

Expression Systems

Screening Compounds

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12370181 - Regimens of estrogen receptor antagonists (2025-07-29),

2. 11672785 - Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs (2023-06-13),

3. 11229630 - Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs (2022-01-25),

4. 10624878 - Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs (2020-04-21),

5. 10292971 - Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs (2019-05-21),

6. 9018244 - Benzopyran compounds, compositions and uses thereof (2015-04-28),

7. 8143226 - Tyrosine kinase receptor antagonists and methods of treatment for breast cancer (2012-03-27),

8. 8063249 - Substituted triphenyl butenes (2011-11-22),

9. 6965850 - Methods for modulating nuclear receptor coactivator binding (2005-11-15),

10. 6884577 - Methods for screening compounds for estrogenic activity (2005-04-26),

11. 6586655 - Expression of human estrogen receptors in transgenic mice (2003-07-01),

12. 6266622 - Nuclear receptor ligands and ligand binding domains (2001-07-24),

13. 6236946 - Nuclear receptor ligands and ligand binding domains (2001-05-22),

14. 6156723 - Compositions comprising inhibitors of estrogen response (2000-12-05),

15. 6117638 - Methods to screen for transcription factor-coactivator interactions (2000-09-12),

Title: The Innovative Contributions of Peter J. Kushner

Introduction

Peter J. Kushner is a notable inventor based in San Francisco, CA, known for his contributions to the field of biotechnology and pharmaceuticals. With a remarkable portfolio of 17 patents, Kushner has made significant strides in cancer treatment and therapeutic advancements.

Latest Patents

Kushner's latest patents reflect his dedication to addressing critical health challenges. One of his notable inventions includes methods of administering estrogen receptor antagonists, aimed at treating cancer. This patent focuses on tetrahydropyrido[3,4-b]indole compounds that serve as complete estrogen receptor antagonists. Additionally, he has developed tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs, which are designed for modulating disorders mediated by estrogen and other related ailments.

Career Highlights

Throughout his career, Peter J. Kushner has collaborated with prominent organizations, including the University of California and Olema Pharmaceuticals, Inc. His work has significantly impacted the pharmaceutical landscape, particularly regarding therapies for hormone-related conditions.

Collaborations

Kushner's journey has been enriched by his collaborations with esteemed colleagues, including Cyrus L. Harmon and David C. Myles. These partnerships have fostered innovation and contributed to the successful development of advanced pharmaceutical solutions.

Conclusion

Peter J. Kushner's inventive spirit and extensive patent portfolio underscore his vital role in advancing medical therapies. His commitment to exploring the potential of estrogen receptor antagonists demonstrates his dedication to improving cancer treatment and enhancing patient outcomes.

Profile summary based on public USPTO records.